BioLineRx Ltd. (NASDAQ:BLRX – Free Report) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for BioLineRx in a report released on Monday, August 31st. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings of ($0.77) per share for the quarter. HC Wainwright also issued estimates for BioLineRx’s Q4 2026 earnings at ($0.80) EPS, FY2026 earnings at ($3.14) EPS and FY2027 earnings at ($2.52) EPS.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, BioLineRx has a consensus rating of “Sell”.
BioLineRx Price Performance
NASDAQ:BLRX opened at $2.76 on Wednesday. BioLineRx has a 12-month low of $2.15 and a 12-month high of $4.56. The firm has a market cap of $12.06 million, a price-to-earnings ratio of -1.63 and a beta of 1.56. The company’s 50-day moving average is $2.90 and its two-hundred day moving average is $2.83. The company has a current ratio of 1.58, a quick ratio of 1.43 and a debt-to-equity ratio of 0.16.
BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its quarterly earnings data on Monday, August 31st. The biotechnology company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.62). BioLineRx had a negative net margin of 502.08% and a negative return on equity of 32.91%. The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.50 million.
BioLineRx Company Profile
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.
Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.
Read More
- Five stocks we like better than BioLineRx
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
